Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on X:
“Analysis using Korean insurance claims data: of 10,275 pts receiving immunotherapy for NSCLC, 7.6% complete planned 2y – no significant difference with various agents. Note that after 3y off therapy, 42% of pts received subsequent treatment.”
Title: Treatment-free survival after two-year immune checkpoint inhibitor treatment in non-small cell lung cancer: Utilizing the Korean Health Insurance Review and Assessment Service database
Authors: Kyoungmin Lee, Minwoong Kang, Yoon Namgung, In Hae Park, Yoon Ji Choi, Jung Sun Kim, Eun Joo Kang
Read the Full Article.
Other articles about lung oncology on OncoDaily.